Vasomune Therapeutics is a biotechnology company developing compounds targeting diseases associated with vascular dysfunction and destabilization. The company’s lead compound is Vasculotide, a Tie2 receptor agonist that is being developed to treat acute lung injury (ALI) and acute kidney injury (AKI).